文献速递泌尿生殖与妇科肿瘤放疗

质子治疗用于局限性前列腺癌管理:综合癌症中心的长期临床结局

Proton therapy for the management of localized prostate cancer: Long-term clinical outcomes at a comprehensive cancer center.
PubMed 文献 · Radiother Oncol · 2023-08-18

本中心回顾性分析2006年5月至2020年1月治疗的2772例局限性前列腺癌患者,按NCCN指南分层为低危、有利中危、不利中危、高危和极高危组,中位随访7.0年。中位剂量78 Gy(1.8-2.0 Gy(RBE)/次),5年和10年生化复发自由率低危组98.2%和96.8%,极高危组86.1%和68.5%;晚期≥3级泌尿和胃肠毒性总发生率分别为0.87%和1.01%。

要点

  • 2772例局限性前列腺癌患者接受质子治疗,中位随访7.0年。
  • 5年FFBR低危组98.2%、有利中危组98.3%、不利中危组94.2%、高危组94.3%、极高危组86.1%。
  • 晚期≥3级泌尿毒性和胃肠毒性总发生率分别为0.87%和1.01%。

核心结论

  • 质子治疗用于局限性前列腺癌在本大样本队列中显示出优异的临床结局,即使在历史上积极治疗预后仍差的较高危组中也是如此。

研究设计与样本

  • 回顾性分析2006年5月至2020年1月在本综合癌症中心接受质子治疗的2772例局限性前列腺癌患者。
  • 按美国国家综合癌症网络(NCCN)指南进行疾病风险分层:低危(LR)640例、有利中危(F-IR)850例、不利中危(U-IR)851例、高危(HR)315例、极高危(VHR)116例。
  • 采用Kaplan-Meier估计和多变量模型分析生化失败和毒性。

主要发现

  • 患者中位年龄66岁,中位随访时间7.0年。
  • 盆腔淋巴结照射用于28例(1%):不利中危组2例(0.2%)、高危组11例(3.5%)、极高危组15例(12.9%)。
  • 中位剂量为78 Gy,分次剂量1.8-2.0 Gy(RBE)。
  • 5年和10年生化复发自由率(FFBR):低危组98.2%和96.8%,有利中危组98.3%和93.6%,不利中危组94.2%和90.2%,高危组94.3%和85.2%,极高危组86.1%和68.5%。
  • 2例患者死于前列腺癌;晚期≥3级泌尿毒性和胃肠毒性总发生率分别为0.87%和1.01%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Proton therapy (PT) has emerged as a standard-of-care treatment option for localized prostate cancer at our comprehensive cancer center. However, there are few large-scale analyses examining the long-term clinical outcomes. Therefore, this article aims to evaluate the long-term effectiveness and toxicity of PT in patients with localized prostate cancer. MATERIALS AND METHODS: Review of 2772 patients treated from May 2006 through January 2020. Disease risk was stratified according to National Comprehensive Cancer Network guidelines as low [LR, n = 640]; favorable-intermediate [F-IR, n = 850]; unfavorable-intermediate [U-IR, n = 851]; high [HR, n = 315]; or very high [VHR, n = 116]. Biochemical failure and toxicity were analyzed using Kaplan-Meier estimates and multivariate models. RESULTS: The median patient age was 66 years; the median follow-up time was 7.0 years. Pelvic lymph node irradiation was prescribed to 28 patients (1%) (2 [0.2%] U-IR, 11 [3.5%] HR, and 15 [12.9%] VHR). The median dose was 78 Gy in 1.8-2.0 Gy(RBE) fractions. Freedom from biochemical relapse (FFBR) rates at 5 years and 10 years were 98.2% and 96.8% for the LR group; 98.3% and 93.6%, F-IR; 94.2% and 90.2%, U-IR; 94.3% and 85.2%, HR; and 86.1% and 68.5%, VHR. Two patients died of prostate cancer. Overall rates of late grade ≥ 3 GU and GI toxicity were 0.87% and 1.01%. CONCLUSIONS: Proton therapy for localized prostate cancer demonstrated excellent clinical outcomes in this large cohort, even among higher-risk groups with historically poor outcomes despite aggressive therapy.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Sosa AJ, Thames HD, Sanders JW, et al. Proton therapy for the management of localized prostate cancer: Long-term clinical outcomes at a comprehensive cancer center. Radiother Oncol. 2023. PMID: 37597805. doi:10.1016/j.radonc.2023.109854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。